MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders
Gemma Olivé-Cirera, Arlette L. Bruijstens, Elianet Fonseca, Li‐Wen Chen, Eva Caballero, Eugenia Martínez‐Hernández, Mar Guasp, María Sepúlveda, Laura Naranjo, Raquel Ruiz‐García, Yolanda Blanco, Albert Saiz, Josep Dalmau, Thaís Armangué, for the Spanish Pediatric MOGAD Study Group
Abstract
OBJECTIVES: To assess the clinical significance of myelin oligodendrocyte glycoprotein antibodies (MOG-abs) restricted to CSF in children with inflammatory CNS disorders. METHODS: Patients included 760 children (younger than 18 years) from 3 multicenter prospective cohort studies: (A) acquired demyelinating syndromes, including acute disseminated encephalomyelitis (ADEM); (B) non-ADEM encephalitis; and (C) noninflammatory neurologic disorders. For all cases, paired serum/CSF samples were systematically examined using brain immunohistochemistry and live cell-based assays. RESULTS: < 0.0001). DISCUSSION: Detection of MOG-abs in serum or CSF is associated with CNS inflammatory disorders. Children with MOG-abs restricted to CSF are more likely to have CSF oligoclonal bands and multiple sclerosis than those with MOG-abs detectable in serum.